Jonsson Comprehensive Cancer Center: Glioblastoma trials

The registry lists 21 Glioblastoma studies with Jonsson Comprehensive Cancer Center as lead sponsor. 5 are open to participants now and 2 have results posted.

Phase 1 7Phase 2 9Phase 3 2No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma PatientsRecruitingNCT07461948Phase 3
• ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG TrialRecruitingNCT07089641Phase 1
• PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With GlioblastomaNot yet recruitingNCT06448286Phase 3
• Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable GlioblastomaRecruitingNCT06090903Not applicable
• Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma CellsRecruitingNCT06059690Phase 1/2
• Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or GliosarcomaCompletedNCT01013285Phase 2Results posted
• Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or GliosarcomaCompletedNCT00998010Phase 2Results posted
• ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent GlioblastomaWithdrawnNCT04854044Phase 1
• Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent GlioblastomaCompletedNCT04201873Phase 1
• 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent GlioblastomaCompletedNCT03732352Phase 2
• Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent GlioblastomaWithdrawnNCT03014804Phase 2
• Delayed 18F-FDG PET/CT in Improving Visualization of Brain Tumors in Patients With GlioblastomaWithdrawnNCT02919332
• FDG PET/CT in Monitoring Very Early Therapy Response in Patients With GlioblastomaCompletedNCT02902757Not applicable
• Palliative 4pi Radiotherapy in Treating Patients With Recurrent Glioblastoma MultiformeCompletedNCT02575027Not applicable
• Response Monitoring Trial in Patients With Suspected Recurrence of GlioblastomaCompletedNCT01813877Not applicable
• Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma MultiformeCompletedNCT01591577Phase 2
• Dendritic Cell Vaccine for Patients With Brain TumorsCompletedNCT01204684Phase 2
• Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or GliosarcomaCompletedNCT01149850Phase 2
• Cellular Immunotherapy Study for Brain CancerCompletedNCT01144247Phase 1
• Sirolimus in Treating Patients With Glioblastoma MultiformeCompletedNCT00047073Phase 1/2
• Motexafin Gadolinium Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00003409Phase 1